×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BHVN – biohaven pharmaceutical holding company ltd. common shares (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BHVN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/26
09:26 am
bhvn
Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise [Seeking Alpha]
High
Report
Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise [Seeking Alpha]
12/26
07:40 am
bhvn
Nvidia, Micron, Nike, Tesla, Biohaven, Coupang, and More Stock Market Movers [Barron's]
High
Report
Nvidia, Micron, Nike, Tesla, Biohaven, Coupang, and More Stock Market Movers [Barron's]
12/26
07:34 am
bhvn
Biohaven defended despite depression trial setback [Seeking Alpha]
High
Report
Biohaven defended despite depression trial setback [Seeking Alpha]
12/26
07:17 am
bhvn
Biohaven (NYSE:BHVN) had its "market perform" rating reaffirmed by analysts at William Blair.
High
Report
Biohaven (NYSE:BHVN) had its "market perform" rating reaffirmed by analysts at William Blair.
12/26
07:17 am
bhvn
Biohaven (NYSE:BHVN) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
High
Report
Biohaven (NYSE:BHVN) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/26
07:17 am
bhvn
Biohaven (NYSE:BHVN) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
High
Report
Biohaven (NYSE:BHVN) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
12/24
04:29 pm
bhvn
Biohaven's depression drug fails mid-stage trial, shares fall [Yahoo! Finance]
High
Report
Biohaven's depression drug fails mid-stage trial, shares fall [Yahoo! Finance]
12/24
01:57 pm
bhvn
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder [Yahoo! Finance]
Neutral
Report
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
06:58 am
BHVN
biohaven pharmaceutical holding company ltd. common shares
BEAT
Report
-7.7%
biohaven pharmaceutical holding company ltd. common shares
8/11/2025
07:00 am
BHVN
biohaven pharmaceutical holding company ltd. common shares
BEAT
Report
-8.2%
biohaven pharmaceutical holding company ltd. common shares
5/12/2025
04:05 pm
BHVN
biohaven pharmaceutical holding company ltd. common shares
BEAT
Report
-5.1%
biohaven pharmaceutical holding company ltd. common shares
3/3/2025
07:30 am
BHVN
biohaven pharmaceutical holding company ltd. common shares
MISS
Report
-14.1%
biohaven pharmaceutical holding company ltd. common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/18
07:29 am
bhvn
Form 4 Biohaven Ltd. For: Nov 17 Filed by: Clark George C.
High
Report
Form 4 Biohaven Ltd. For: Nov 17 Filed by: Clark George C.
11/17
07:31 am
bhvn
Form 4 Biohaven Ltd. For: Nov 13 Filed by: Bailey Gregory
Low
Report
Form 4 Biohaven Ltd. For: Nov 13 Filed by: Bailey Gregory
11/17
07:31 am
bhvn
Form 4 Biohaven Ltd. For: Nov 13 Filed by: CHILDS JOHN W
Low
Report
Form 4 Biohaven Ltd. For: Nov 13 Filed by: CHILDS JOHN W
11/17
07:30 am
bhvn
Form 4 Biohaven Ltd. For: Nov 13 Filed by: Coric Vlad
Low
Report
Form 4 Biohaven Ltd. For: Nov 13 Filed by: Coric Vlad
11/14
10:29 am
bhvn
Form SCHEDULE 13G Biohaven Ltd. Filed by: JANUS HENDERSON GROUP PLC
Medium
Report
Form SCHEDULE 13G Biohaven Ltd. Filed by: JANUS HENDERSON GROUP PLC
11/10
08:12 am
bhvn
Form 10-Q Biohaven Ltd. For: Sep 30
Medium
Report
Form 10-Q Biohaven Ltd. For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/16
Form DEFA14A Biohaven Pharmaceutical
14.2%
2/10 Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List 12.9%
7/22 Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled 10.4%
9/4 Form 8-K Biohaven Pharmaceutical For: Sep 04 9.3%
2/27 Biohaven's NURTEC™ ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults 8.1%
7/15 Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet 7.6%
3/12 Form 5 Biohaven Pharmaceutical For: Dec 31 Filed by: Coric Vlad 7.2%
5/7 Form 8-K Biohaven Pharmaceutical For: May 07 6.5%
4/27 Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC™ ODT in the Middle East 5.9%
1/27 Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%
2/10 Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List 12.9%
7/22 Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled 10.4%
9/4 Form 8-K Biohaven Pharmaceutical For: Sep 04 9.3%
2/27 Biohaven's NURTEC™ ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults 8.1%
7/15 Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet 7.6%
3/12 Form 5 Biohaven Pharmaceutical For: Dec 31 Filed by: Coric Vlad 7.2%
5/7 Form 8-K Biohaven Pharmaceutical For: May 07 6.5%
4/27 Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC™ ODT in the Middle East 5.9%
1/27 Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%
TOP News Decliners
3/31
Form 8-K Biohaven Pharmaceutical For: Mar 30
-13.6%
6/17 Biohaven Announces Proposed Public Offering Of Common Shares -12.4%
1/10 Form 4 Biohaven Pharmaceutical For: Jan 08 Filed by: Stock Elyse -11.2%
12/17 Biohaven Pharma says acute migraine treatment succeeds in study [Reuters] -10.7%
1/28 Biohaven Announces Proposed Public Offering Of Common Shares -8.8%
6/18 Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares -7.2%
12/6 Biohaven Pharma to continue late-stage study of Alzheimer's treatment [Reuters] -7.0%
4/7 Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC™ ODT -5.9%
2/10 Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint -5.9%
3/30 Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine -5.0%
6/17 Biohaven Announces Proposed Public Offering Of Common Shares -12.4%
1/10 Form 4 Biohaven Pharmaceutical For: Jan 08 Filed by: Stock Elyse -11.2%
12/17 Biohaven Pharma says acute migraine treatment succeeds in study [Reuters] -10.7%
1/28 Biohaven Announces Proposed Public Offering Of Common Shares -8.8%
6/18 Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares -7.2%
12/6 Biohaven Pharma to continue late-stage study of Alzheimer's treatment [Reuters] -7.0%
4/7 Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC™ ODT -5.9%
2/10 Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint -5.9%
3/30 Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine -5.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: